Syntropy to unlock the value of scientific data in fight to end cancer
- Details
- Category: Merck Group
Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syntropy. Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives.
Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer
- Details
- Category: Merck Group
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival (OS) or progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer.
MSD is looking for a digital health solution to empower oncologists by keeping them updated in their field
- Details
- Category: Business
MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The solution should consider several channels (web, app, email newsletter, social media, etc) and adapt to the preferences to each user, so they are motivated to access the content regularly over time.
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults. Lasmiditan is an investigational, oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies and lacks vasoconstrictive activity.
Abbott recommends rejection of below-market mini-Ttender offer by Baker Mills LLC
- Details
- Category: Abbott
Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company's outstanding shares.
AstraZeneca to divest US Synagis rights to Sobi
- Details
- Category: AstraZeneca
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
- Details
- Category: Novo Nordisk
Embark Biotech ApS and Novo Nordisk A/S have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure.
More Pharma News ...
- FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
- Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
- Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
- Amgen Foundation deepens commitment to aspiring scientists worldwide by expanding Amgen Scholars Program
- Boehringer Ingelheim inaugurates new centre for agile working methods
- Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
- Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH